Published in Nucleic Acids Res on December 02, 2014
The delivery of therapeutic oligonucleotides. Nucleic Acids Res (2016) 0.82
Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy. Nucleic Acid Ther (2017) 0.77
Advances in gene therapy for muscular dystrophies. F1000Res (2016) 0.75
An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes. RSC Adv (2017) 0.75
Nanotherapy for Duchenne muscular dystrophy. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2017) 0.75
Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature (1997) 14.82
Transcriptional control by the TGF-beta/Smad signaling system. EMBO J (2000) 8.49
X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A (1984) 8.35
Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med (2007) 7.29
Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A (2001) 6.38
Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med (2011) 5.91
Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol (2009) 5.35
Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol (2013) 4.57
Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med (2006) 3.74
Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem (2002) 3.07
Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol (2002) 3.03
Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol (2009) 3.01
Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther (2008) 2.69
Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther (2006) 2.00
Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov (2011) 1.89
Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat (2007) 1.89
Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA (2007) 1.78
Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet (2008) 1.69
Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res (2008) 1.52
Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet (2003) 1.52
Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug Chem (2007) 1.46
Methods and protocols of modern solid phase Peptide synthesis. Mol Biotechnol (2006) 1.42
Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucleic Acids (2012) 1.41
Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A (2012) 1.32
Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res (2007) 1.28
Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies. Discov Med (2013) 1.27
Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem Soc Trans (2007) 1.17
Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol Ther (2010) 1.10
Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment. Mol Ther (2010) 1.03
Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol Ther (2010) 1.01
A chemical view of oligonucleotides for exon skipping and related drug applications. Nucleic Acid Ther (2013) 1.00
A new micro-test for the detection of incomplete coupling reactions in solid-phase peptide synthesis using 2,4,6-trinitrobenzenesulphonic acid. Anal Biochem (1976) 0.98
Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice. Hum Mol Genet (2013) 0.95
Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther (2012) 0.95
Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy. BMC Med Genet (2008) 0.95
Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice. Am J Pathol (2010) 0.94
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Med Genomics (2011) 0.92
Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy. Mol Ther Nucleic Acids (2012) 0.89
Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. Nucleic Acids Res (2013) 0.86
Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice. Hum Gene Ther (2012) 0.83
Interleukin-6 and interleukin-10 are expressed in organs of normal young and old mice. Eur Cytokine Netw (2004) 0.82
Development of a general methodology for labelling peptide-morpholino oligonucleotide conjugates using alkyne-azide click chemistry. Chem Commun (Camb) (2013) 0.81
Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor. Mol Ther Nucleic Acids (2014) 0.79
Guided reconstitution of membrane protein fragments. Biopolymers (2014) 0.77
Development of a multiplex allele-specific primer PCR assay for simultaneous detection of QoI and CAA fungicide resistance alleles in Plasmopara viticola populations. Pest Manag Sci (2012) 0.77
Design and application of bispecific splice-switching oligonucleotides. Nucleic Acid Ther (2014) 0.77
How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse. Hum Mol Genet (2015) 1.07
Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration. Hum Mol Genet (2015) 0.95
Oligonucleotide-Based Therapy for FTD/ALS Caused by the C9orf72 Repeat Expansion: A Perspective. J Nucleic Acids (2013) 0.75
Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis Model Mech (2017) 0.75